Noted guitarist Perry Lederman and Grateful Dead great Jerry Garcia met in the Berkeley, California, folk scene in the early 1960s. When a fire destroyed Lederman's home in 1979, Garcia gave him the Byrdland guitar at right so he would have an instrument to play. They stayed in touch, and around 1992, when Garcia sent Lederman documentation about his previous ownership of the guitar, he also contributed to Lederman's medical bills after he was diagnosed with Non-Hodgkin's lymphoma.
Garcia last saw Lederman when he invited the family backstage for a Dead concert at the Boston Garden on September 27, 1994. Lederman passed away eight months later, in May 1995, and Garcia died three months after that. Both were 53.
The guitar is a typical 1960s Byrdland with Florentine cutaway, except for the obvious - the Bigsby tailpiece that came off a Gretsch. The instrument is being offered by the current owner for $100,000 here. Ouch.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...